Zymeworks has wrapped up its takeover of Theravance Biopharma, adding new drugs and royalties to its portfolio and pushing for steadier revenue.
A new study shows that two common mutations in clonal haematopoiesis trigger inflammation in aging blood cells, but each does it in its own way. This could lead to new biomarkers and targeted treatments.
Sai Life Sciences now holds a license to ERS Genomics' CRISPR Cas9 patents, opening up advanced genome editing for its research and development services worldwide.
SOHO 2026 brought sharp updates on secondary cancer risks after CAR T-cell therapy, new MDS trial results, and changing CLL treatment plans. The meeting marks a real shift in how blood cancers are managed.
GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.
